Mechanism and clinical research progress of remifentanil in the prevention and treatment of emergence agitation
10.6039/j.issn.1001-0408.2025.15.23
- VernacularTitle:瑞芬太尼防治苏醒期躁动的作用机制及临床研究进展
- Author:
Na WANG
1
;
Yongbo DUAN
;
Zhongjie XIAO
;
Yujing SONG
;
Wenjun YAN
Author Information
1. 甘肃中医药大学第一临床医学院,兰州 730099;甘肃省人民医院麻醉科,兰州 730013
- Publication Type:Journal Article
- Keywords:
remifentanil;
emergence agitation;
neuroimmune mechanisms;
clinical applications
- From:
China Pharmacy
2025;36(15):1947-1952
- CountryChina
- Language:Chinese
-
Abstract:
Emergence agitation(EA)is a common complication after general anesthesia,especially in children and adolescents.Remifentanil,as a short-acting μ-receptor agonist,has become an important drug for the prevention and treatment of EA due to its rapid recovery and low risk of respiratory depression.This article reviews the mechanism of action and clinical research progress of remifentanil in the prevention and treatment of EA.Its mechanism of action involves the inhibition of pain signals mediated by traditional μ-receptor activation and potential new mechanism based on neural-endocrine-immune network,including regulation of microglial inflammatory pathways,and the modulation of cytokines and chemokines,etc.Clinical studies have shown that remifentanil can significantly shorten the recovery time,reduce the incidence of EA,and further optimize the analgesic effect and recovery quality by combining with other drugs(such as local anesthetics,sedatives,and opioid drugs).Future research should further explore the mechanism of action of remifentanil,optimize clinical treatment strategies,and conduct large-scale clinical trials to standardize the drug use plan,while paying attention to its long-term effects and the development of multimodal treatment plans to promote the further development of EA prevention and treatment plans.
